Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Brain metastases in de novo breast cancer: An updated population-level study from SEER database.Asian J Surg. 2022; https://doi.org/10.1016/j.asjsur.2021.12.037
- Characterization of bone only metastasis patients with respect to tumor subtypes.NPJ Breast Cancer. 2018; 4: 2
- Breast cancer brain metastases: the last frontier.Exp Hematol Oncol. 2015; 4: 33
- Management of metastatic (parenchymal, leptomeningeal, and epidural) lesions.Curr Opin Oncol. 2004; 16: 309-313
- Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.NPJ Breast Cancer. 2022; 8: 37
- Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).ESMO Open. 2021; 6: 100220
- Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.NPJ Breast Cancer. 2022; 8: 46
- Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today.Int J Radiat Oncol Biol Phys. 2020; 107: 334-343
- Graded Prognostic Assessment (GPA) tool.(Available at:) (Accessed July 5, 2022)
- Leptomeningeal carcinomatosis in patients with breast cancer.Crit Rev Oncol Hematol. 2019; 135: 85-94
- Emergency neurological life support: spinal cord compression (SCC).Neurocrit Care. 2012; 17: S96-S101
- Diagnosis and treatment of epidural metastases.Cancer. 2017; 123: 1106-1114
- Bridging barriers: a comparative look at the blood-brain barrier across organisms.Genes Dev. 2018; 32: 466-478
- Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.Nat Commun. 2022; 13: 514
- Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors.Nat Commun. 2021; 12: 6692
- Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity.Cancer Discov. 2022; 12: 1199-1216
- PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.Glia. 2018; 66: 2438-2455
- Structure and function of the blood-brain barrier.Neurobiol Dis. 2010; 37: 13-25
- The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.Nat Rev Cancer. 2020; 20: 26-41
- The blood-tumour barrier in cancer biology and therapy.Nat Rev Clin Oncol. 2021; 18: 696-714
- Symptomatic management and imaging of brain metastases.J Neurooncol. 2005; 75: 15-20
- Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer.JAMA Oncol. 2018; 4: 1001-1003
- Brain Metastasis Velocity: A Novel Prognostic Metric Predictive of Overall Survival and Freedom From Whole-Brain Radiation Therapy After Distant Brain Failure Following Upfront Radiosurgery Alone.Int J Radiat Oncol Biol Phys. 2017; 98: 131-141
- Multidisciplinary brain metastasis clinic: is it effective and worthwhile?.Ecancermedicalscience. 2020; 14: 1136
- A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.Oncologist. 2016; 21: 16-20
- A randomized trial of surgery in the treatment of single metastases to the brain.N Engl J Med. 1990; 322: 494-500
- Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?.Ann Neurol. 1993; 33: 583-590
- A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis.Cancer. 1996; 78: 1470-1476
- Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial.Lancet Oncol. 2017; 18: 1049-1060
- Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases.Int J Radiat Oncol Biol Phys. 1998; 42: 155-159
- Surgical advances in the management of brain metastases.Neurooncol Adv. 2021; 3: v4-v15
- Early postoperative MRI after resection of brain metastases-complete tumour resection associated with prolonged survival.Acta Neurochir (Wien). 2019; 161: 555-565
- Reduced local recurrence of a single brain metastasis through microscopic total resection.J Neurosurg. 2009; 110: 730-736
- The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting.Cancers (Basel). 2021; : 13https://doi.org/10.3390/cancers13061435
- The role of surgical resection in the management of brain metastasis: a 17-year longitudinal study.Acta Neurochir (Wien). 2013; 155: 389-397
- Management of brain metastases: history and the present.Chin Neurosurg J. 2019; 5: 1
- The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system.Int J Radiat Oncol Biol Phys. 1981; 7: 897-906
- Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.Int J Radiat Oncol Biol Phys. 1997; 37: 745-751
- Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.Lancet. 2016; 388: 2004-2014
- Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.J Clin Oncol. 2020; 38: 1019-1029
- Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.Neuro Oncol. 2013; 15: 1429-1437
- Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.JAMA. 2006; 295: 2483-2491
- Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.Int J Radiat Oncol Biol Phys. 2007; 68: 1388-1395
- Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.JAMA. 2016; 316: 401-409
- A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4-10 brain metastases.Neurooncol Adv. 2021; 3: vdab021
- Stereotactic Radiosurgery versus Whole-brain Radiation Therapy for Patients with 4-15 Brain Metastases: A Phase III Randomized Controlled Trial [abstract].Int J Radiat Oncol Biol Phys. 2020; 108: S21-S22
- Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.Breast Cancer Res Treat. 2019; 176: 171-179
- Response of brain metastases from breast cancer to systemic chemotherapy.Cancer. 1992; 69: 972-980
- Salvage Treatment for Progressive Brain Metastases in Breast Cancer.Cancers (Basel). 2022; 14https://doi.org/10.3390/cancers14041096
- Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).Eur J Cancer. 2003; 39: 1271-1276
- Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.Ann Oncol. 2015; 26: 89-94
- High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?.J Clin Oncol. 1998; 16: 1561-1567
- High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature.Hematol Oncol Stem Cell Ther. 2019; 12: 189-193
- [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].Bull Cancer. 2016; 103 (Methotrexate intrathecal dans les meningites carcinomateuses du cancer du sein - Experience avec le protocole utilise a l'hopital Saint-Louis): 444-454
- Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.ESMO Open. 2021; 6: 100150
- Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.Int J Cancer. 2016; 139: 1864-1872
- Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer.Clin Breast Cancer. 2019; 19: 311-316
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2008; 26: 1993-1999
- Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.Clin Cancer Res. 2009; 15: 1452-1459
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.J Neurooncol. 2011; 105: 613-620
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.Lancet Oncol. 2013; 14: 64-71
- Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.Front Oncol. 2020; 10: 576926
- CTNI-05. NRG Oncology/RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery with Concurent Lapatinib in Patients with Brain Metastases from HER2-positive Breast Cancer [abstract].Neuro Oncol. 2020; 22: ii42
- Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.Clin Breast Cancer. 2020; 20: 145-151 e2
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.J Clin Oncol. 2019; 37: 1081-1089
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial.J Clin Oncol. 2020; 38: 3138-3149
Dinkel V, Anderson DH, Winski S, Winkler J, Koch K, Lee PA. ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice [abstract]. AACR 103rd Annual Meeting 2012-- Mar 31-Apr 4, 2012; Chicago, IL. 2012.
- Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.Proc Natl Acad Sci U S A. 2022; : 119https://doi.org/10.1073/pnas.2112491119
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med. 2020; 382: 597-609
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.J Clin Oncol. 2020; 38: 2610-2619
- Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) [abstract].J Clin Oncol. 2021; 39: 1043
- Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB).Cancer Res. 2022; 82: PD4-PD05
- Trastuzumab containing regimens for early breast cancer.Cochrane Database Syst Rev. 2012; : CD006243
- Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.Cancer. 2011; 117: 1837-1846
Piccart M, Procter M, Fumagalli D, et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): Aacr; Cancer Res 2020;80(4 Suppl):Abstract nr GS1-04.
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med. 2019; 380: 617-628
- Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.Anticancer Drugs. 2007; 18: 23-28
- Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.Breast Cancer Res Treat. 2017; 164: 581-591
- Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.J Clin Oncol. 2021; 39: 2667-2675
- Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.Cancer Treat Rev. 2020; 88: 102046
- Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort.Int J Cancer. 2022; https://doi.org/10.1002/ijc.34135
- LPTO-02. Intrathecal (IT) Trastuzumab (T) for the Treatment of Leptomeningeal Disease (LM) in Patients (PTS) with Human Epidermal Receptor 2 Positive (HER2+) Cancer: A Multicenter Phase 1/2 Study [abstract].Neurooncol Adv. 2019; 1: i6
- Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.Eur J Cancer. 2018; 95: 75-84
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.Ann Oncol. 2020; 31: 1350-1358
Hurvitz S, Kim SB, Chung WP, et al. Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03 [abstract], Cancer Res, 82 (4_supplement), 2022, GS3-01.
- Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases.Oncologist. 2022; 27: S3-S4
- Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study.Cancer Res. 2022; 82: PD4-PD06
- 165MO - Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial [abstract].Ann Oncol. 2022; 33: S194-S223
- Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM).Cancer Res. 2022; 82: PD4-PD05
- Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.Clin Exp Metastasis. 2004; 21: 107-118
- US Food and Drug Administration. Proposal to Withdraw Approval for the Breast Cancer Indication for AVASTIN (Bevacizumab).https://www.fda.gov/media/82467/download. 2011Date accessed: July 12, 2022
- Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.Breast Cancer Res. 2020; 22: 131
- Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.Clin Cancer Res. 2015; 21: 1851-1858
- Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases.Neurooncol Adv. 2020; 2: vdaa038
- Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review.Front Oncol. 2021; 11: 593449
- A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.Clin Cancer Res. 2020; 26: 5310-5319
- LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.Breast Cancer Res Treat. 2018; 171: 637-648
- Abstract PD13-05: Delivery and activity of SN-38 by sacituzumab govitecan in breast cancer brain metastases [asbtract].Cancer Res. 2021; 81 (PD13-05)
- Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib.JCO Precis Oncol. 2020; 4https://doi.org/10.1200/PO.19.00403
- Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.NPJ Breast Cancer. 2019; 5: 46
- HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Nat Commun. 2021; 12: 6667
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
